Mosaiques Diagnostics
Mosaiques Diagnostics specializes in proteomic analysis to scan the body at a molecular level, providing benefits for managing chronic diseases including cancer. They utilize proteome analysis for early disease detection and personalized medicine, marking a significant advancement in biomarker discovery and clinical diagnostics. The company is a leader in clinical proteome analysis, with over 400 scientific publications and collaborations with over 85 universities and research institutes worldwide. They develop diagnostic peptide patterns from body fluids like urine and bile for early and differential detection of diseases such as kidney diseases, cardiovascular diseases, cancer, and graft-versus-host disease, aiming to improve patient care and enable personalized medicine.
Industries
Nr. of Employees
small (1-50)
Mosaiques Diagnostics
Hannoversch Münden, Niedersachsen, Germany, Europe
Products
Curated urinary proteome/peptidome reference resource
A curated repository of endogenous urinary peptides and proteins to support peptide identification, classifier development and cross-study comparisons.
Validated urinary peptide-based diagnostic classifiers
A set of validated urine (and other biofluid) peptide-based classifiers for multiple clinical indications (including chronic kidney disease, graft rejection/GvHD, bladder and prostate cancer, cholangiocarcinoma and acute conditions such as severe COVID-19), developed and evaluated in multicentre cohorts.
Urine-based laboratory diagnostic assays (IVD channel)
Laboratory-implemented urine-based diagnostic tests marketed through diagnostic distribution channels to enable clinical detection and monitoring for selected indications.
Curated urinary proteome/peptidome reference resource
A curated repository of endogenous urinary peptides and proteins to support peptide identification, classifier development and cross-study comparisons.
Validated urinary peptide-based diagnostic classifiers
A set of validated urine (and other biofluid) peptide-based classifiers for multiple clinical indications (including chronic kidney disease, graft rejection/GvHD, bladder and prostate cancer, cholangiocarcinoma and acute conditions such as severe COVID-19), developed and evaluated in multicentre cohorts.
Urine-based laboratory diagnostic assays (IVD channel)
Laboratory-implemented urine-based diagnostic tests marketed through diagnostic distribution channels to enable clinical detection and monitoring for selected indications.
Services
Clinical proteomics laboratory services
On-site laboratory proteomic and peptidomic analyses for research, diagnostics development and clinical study support using mass spectrometry-based workflows.
Bioinformatics and statistical analysis for omics
Data analysis pipelines, statistical evaluation and machine-learning frameworks for interpretation and integration of proteomic and multi-omics datasets.
Regulatory and clinical-trial biomarker support
Advisory and operational support for biomarker qualification, regulatory interactions and incorporation of proteomic classifiers into clinical trial design and patient stratification.
AI-based drug repurposing and preclinical evaluation
Computational integration of patient-derived multi-omics signatures with AI algorithms to nominate repurposing candidates, followed by in vitro and in vivo efficacy testing.
Clinical proteomics laboratory services
On-site laboratory proteomic and peptidomic analyses for research, diagnostics development and clinical study support using mass spectrometry-based workflows.
Bioinformatics and statistical analysis for omics
Data analysis pipelines, statistical evaluation and machine-learning frameworks for interpretation and integration of proteomic and multi-omics datasets.
Regulatory and clinical-trial biomarker support
Advisory and operational support for biomarker qualification, regulatory interactions and incorporation of proteomic classifiers into clinical trial design and patient stratification.
AI-based drug repurposing and preclinical evaluation
Computational integration of patient-derived multi-omics signatures with AI algorithms to nominate repurposing candidates, followed by in vitro and in vivo efficacy testing.
Expertise Areas
- Clinical proteomics and peptidomics
- Urinary biomarker discovery and validation
- Multi-omics integration and systems biology
- AI-driven drug repurposing and preclinical evaluation
Key Technologies
- Capillary electrophoresis–mass spectrometry (CE‑MS)
- MALDI and LC‑MS/MS mass spectrometry
- Targeted MRM protein quantification
- Urinary peptidomics/proteomics